File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance

TitleLongitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance
Authors
KeywordsHBV
Anti-HBc
Anti-HBs
HBsAg
Hs-HBsAg
Issue Date2016
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2016, v. 36 n. 5, p. 642-650 How to Cite?
AbstractBackground & Aims: Serologic profiles after hepatitis B surface antigen (HBsAg) seroclearance in chronic hepatitis B (CHB) have not been well‐studied. Methods: We employed a highly sensitive HBsAg (hs‐HBsAg) assay (lower detection limit 0.5 mIU/ml), 100 times more sensitive than conventional HBsAg measurements. CHB patients achieving HBsAg seroclearance defined by conventional assays were followed up for serum hs‐HBsAg, HBV DNA and antibody to HBsAg (anti‐HBs) levels at 0 months, 6–12 months and 3–5 years after HBsAg seroclearance. Factors associated with hs‐HBsAg detectability were determined. Results: One hundred and nine patients were recruited; 94 (86.2%) were followed up to years 3–5; and 25 patients (22.9%) were on nucleoside analogue therapy for a median duration of 6.0 (range 1.5–12.7) years before HBsAg seroclearance. Detectable hs‐HBsAg was noted in 88 (80.7%), 60 (55.0%) and 20 (21.3%) patients at 0 months, 6–12 months and 3–5 years respectively. At years 3–5, genotype B patients, when compared to genotype C patients, had a higher anti‐HBs positive rate (63.2% and 41.1% respectively, P = 0.036). Serum anti‐HBs positivity, when compared to persistent anti‐HBs negativity, was associated with a lower rate of hs‐HBsAg detection (7.4% and 40% respectively, P < 0.001). Multivariate analysis showed anti‐HBs negativity at years 3–5 to be independently associated with persistently positive hs‐HBsAg (P = 0.007, odds ratio 7.1, 95% confidence interval 1.7–29.3). Conclusion: Serum hs‐HBsAg could detect HBsAg presence in a substantial proportion of CHB after HBsAg seroclearance defined by conventional assays, especially among anti‐HBs negative individuals. Serum hs‐HBsAg could potentially assist differentiating HBsAg‐negative CHB from individuals with only past HBV exposure without carrier state.
Persistent Identifierhttp://hdl.handle.net/10722/226361
ISSN
2019 Impact Factor: 5.175
2015 SCImago Journal Rankings: 1.677
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKW-
dc.contributor.authorTanaka, Y-
dc.contributor.authorWong, DKH-
dc.contributor.authorShinkai, N-
dc.contributor.authorCheung, KSM-
dc.contributor.authorLiu, SHK-
dc.contributor.authorFung, JYY-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2016-06-17T07:43:37Z-
dc.date.available2016-06-17T07:43:37Z-
dc.date.issued2016-
dc.identifier.citationLiver International, 2016, v. 36 n. 5, p. 642-650-
dc.identifier.issn1478-3223-
dc.identifier.urihttp://hdl.handle.net/10722/226361-
dc.description.abstractBackground & Aims: Serologic profiles after hepatitis B surface antigen (HBsAg) seroclearance in chronic hepatitis B (CHB) have not been well‐studied. Methods: We employed a highly sensitive HBsAg (hs‐HBsAg) assay (lower detection limit 0.5 mIU/ml), 100 times more sensitive than conventional HBsAg measurements. CHB patients achieving HBsAg seroclearance defined by conventional assays were followed up for serum hs‐HBsAg, HBV DNA and antibody to HBsAg (anti‐HBs) levels at 0 months, 6–12 months and 3–5 years after HBsAg seroclearance. Factors associated with hs‐HBsAg detectability were determined. Results: One hundred and nine patients were recruited; 94 (86.2%) were followed up to years 3–5; and 25 patients (22.9%) were on nucleoside analogue therapy for a median duration of 6.0 (range 1.5–12.7) years before HBsAg seroclearance. Detectable hs‐HBsAg was noted in 88 (80.7%), 60 (55.0%) and 20 (21.3%) patients at 0 months, 6–12 months and 3–5 years respectively. At years 3–5, genotype B patients, when compared to genotype C patients, had a higher anti‐HBs positive rate (63.2% and 41.1% respectively, P = 0.036). Serum anti‐HBs positivity, when compared to persistent anti‐HBs negativity, was associated with a lower rate of hs‐HBsAg detection (7.4% and 40% respectively, P < 0.001). Multivariate analysis showed anti‐HBs negativity at years 3–5 to be independently associated with persistently positive hs‐HBsAg (P = 0.007, odds ratio 7.1, 95% confidence interval 1.7–29.3). Conclusion: Serum hs‐HBsAg could detect HBsAg presence in a substantial proportion of CHB after HBsAg seroclearance defined by conventional assays, especially among anti‐HBs negative individuals. Serum hs‐HBsAg could potentially assist differentiating HBsAg‐negative CHB from individuals with only past HBV exposure without carrier state.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1-
dc.relation.ispartofLiver International-
dc.rightsThis is the peer reviewed version of the following article: Liver International, 2016, v. 36 n. 5, p. 642-650, which has been published in final form at http://dx.doi.org/10.1111/liv.12980. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectHBV-
dc.subjectAnti-HBc-
dc.subjectAnti-HBs-
dc.subjectHBsAg-
dc.subjectHs-HBsAg-
dc.titleLongitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance-
dc.typeArticle-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailLiu, SHK: drkliu@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/liv.12980-
dc.identifier.pmid26474013-
dc.identifier.scopuseid_2-s2.0-84949024505-
dc.identifier.hkuros258638-
dc.identifier.volume36-
dc.identifier.issue5-
dc.identifier.spage642-
dc.identifier.epage650-
dc.identifier.isiWOS:000374770600005-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats